{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:48:02Z","timestamp":1785757682490,"version":"3.56.0"},"reference-count":45,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Primary HPV screening has high sensitivity in detecting premalignant and malignant cervical lesions. However, due to its relatively low specificity, this screening approach requires triage tests. Owing to its high specificity, cytology is most commonly employed in the triage of HPV-positive results. Nevertheless, the question remains as to how reliable cytology is in triaging these cases, given its relatively low sensitivity. This study evaluates the clinical significance of high-risk HPV (hrHPV) positivity in women with negative or low-grade cytological findings and assesses whether further evaluation can be safely deferred using HPV genotyping, colposcopy, and p16\/Ki-67 biomarkers. Materials and Methods: A prospective hospital-based observational study was conducted on 125 women with a positive hrHPV cervical test. All participants underwent conventional cytology, extended HPV genotyping, colposcopy, and histopathological evaluation via biopsy or loop excision. Immunohistochemical analysis of p16 and Ki-67 expressions was performed on histopathological tissue samples. Particular attention was focused on women with negative for intraepithelial lesion or malignancy (NILM) and low-grade cytological findings. Associations between cytology, HPV genotype distribution, colposcopic findings, histopathology, smoking status, and biomarker expression were analyzed. Results: Among HPV-positive patients with NILM cytology, CIN2+ lesions were histopathologically confirmed in 28.0% of cases. More than half (51.4%) of all CIN2+ lesions detected in HPV-positive women were identified in patients with low-grade or negative cytology. HPV16\/18 positivity was highly prevalent among women with CIN2+ lesions and low-grade cytological findings (78.4%). Unsatisfactory colposcopy with a non-visible squamocolumnar junction (transformation zone type 3, TZ3) was identified in more than half of these patients. Immunohistochemical markers p16 and Ki-67 demonstrated high sensitivity (95.5%) and negative predictive value (93.3%) for detecting CIN2+ lesions in hrHPV-positive women with low-grade cytology (NILM, ASC-US, and LSIL). Smoking status was significantly associated with CIN2+ lesions in this patient group (p &lt; 0.001). Conclusions: Deferring further evaluation of hrHPV-positive women solely based on negative cytology may be unsafe, particularly in older women, smokers, and those positive for HPV16\/18. The strong association between p16\/Ki-67 positivity and CIN2+ lesions suggests that dual-stain testing directly from cytological samples could significantly improve triage strategies and reduce the need for invasive procedures.<\/jats:p>","DOI":"10.3390\/medicina62081493","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:24:07Z","timestamp":1785752647000},"page":"1493","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Significance of High-Risk HPV Positivity with Negative Cytology: Can Further Evaluation Be Safely Delayed?"],"prefix":"10.3390","volume":"62","author":[{"given":"Aleksandar R.","family":"\u017divadinovi\u0107","sequence":"first","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, University Clinical Center Ni\u0161, 18000 Ni\u0161, Serbia"},{"name":"Faculty of Medicine, University of Nis, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra N.","family":"Petri\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, University Clinical Center Ni\u0161, 18000 Ni\u0161, Serbia"},{"name":"Faculty of Medicine, University of Nis, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazar R.","family":"\u017divadinovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, University Clinical Center Ni\u0161, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-6681","authenticated-orcid":false,"given":"Ivan R.","family":"Ili\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nis, 18000 Ni\u0161, Serbia"},{"name":"Center for Pathology and Pathological Anatomy, University Clinical Center Ni\u0161, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1877-1985","authenticated-orcid":false,"given":"Du\u0161an D.","family":"Simi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nis, 18000 Ni\u0161, Serbia"},{"name":"Women\u2019s Health Protection Office, Health Center Ni\u0161, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8367-3440","authenticated-orcid":false,"given":"Sonja Z.","family":"Pop-Trajkovi\u0107 Dini\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, University Clinical Center Ni\u0161, 18000 Ni\u0161, Serbia"},{"name":"Faculty of Medicine, University of Nis, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan S.","family":"Trenki\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, University Clinical Center Ni\u0161, 18000 Ni\u0161, Serbia"},{"name":"Faculty of Medicine, University of Nis, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena D.","family":"Milo\u0161evi\u0107 Stevanovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, University Clinical Center Ni\u0161, 18000 Ni\u0161, Serbia"},{"name":"Faculty of Medicine, University of Nis, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8472-9282","authenticated-orcid":false,"given":"Nata\u0161a K.","family":"Ran\u010di\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nis, 18000 Ni\u0161, Serbia"},{"name":"Institute for Public Health Ni\u0161, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","first-page":"e70090","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"International Agency for Research and Treatment of Cancer (IARC) Biological Agents (2012). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, IARC. Available online: https:\/\/publications.iarc.who.int\/Book-And-Report-Series\/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans\/Biological-Agents-2012."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41571-024-00904-z","article-title":"Epidemiology of HPV-associated cancers past, present and future: Towards prevention and elimination","volume":"21","author":"Franco","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","unstructured":"ICO\/IARC Information Centre on HPV and Cancer (2023). Serbia: Human Papillomavirus and Related Cancers, Fact Sheet 2023, HPV Information Centre."},{"key":"ref_5","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024). Global Cancer Observatory: Cancer Today. Serbia, Globocan 2022, International Agency for Research on Cancer."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zampaoglou, E., Boureka, E., Gounari, E., Liasidi, P.N., Kalogiannidis, I., Tsimtsiou, Z., Haidich, A., Tsakiridis, I., and Dagklis, T. (2025). Screening for Cervical Cancer: A Comprehensive Review of Guidelines. Cancers, 17.","DOI":"10.3390\/cancers17132072"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Gardella, B., Gritti, A., Soleymaninejadian, E., Pasquali, M.F., Riemma, G., La Verde, M., Schettino, M.T., Fortunato, N., Torella, M., and Dominoni, M. (2022). New Perspectives in Therapeutic Vaccines for HPV: A Critical Review. Medicina, 58.","DOI":"10.3390\/medicina58070860"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"15284","DOI":"10.1002\/cam4.6109","article-title":"Diagnostic value of high-risk HPV other than type 16\/18 in high-grade cervical neoplasia among cytology-negative women: A multicenter retrospective study","volume":"12","author":"Bai","year":"2023","journal-title":"Cancer Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejogrb.2017.03.029","article-title":"A model to evaluate the costs and clinical effectiveness of human papilloma virus screen ing compared with annual papanicolaou cytology in Germany","volume":"212","author":"Petry","year":"2017","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_10","unstructured":"World Health Organization (WHO) (2020). Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem, World Health Organization."},{"key":"ref_11","first-page":"69","article-title":"Knowledge about cervical cancer, Pap test, and barriers to women\u2019s participation in screening in Belgrade, Serbia","volume":"38","author":"Jovanovic","year":"2017","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_12","first-page":"31","article-title":"Cervical cancer screening in Serbia","volume":"31","year":"2007","journal-title":"Coll. Antropol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40944-018-0221-x","article-title":"Evaluation of sensitivity and specificity of Pap Smear, LBC and HPV in screening of cervical cancer","volume":"16","author":"Pankaj","year":"2018","journal-title":"Indian J. Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1086\/516784","article-title":"A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion","volume":"195","author":"Plummer","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.mcna.2022.10.006","article-title":"Cervical cancer screening","volume":"107","author":"Gavinski","year":"2023","journal-title":"Med. Clin. N. Am."},{"key":"ref_18","first-page":"e31312","article-title":"Cervical cancer: Early detection and prevention in reproductive age group","volume":"14","author":"Basoya","year":"2022","journal-title":"Cureus"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/AOG.0000000000000669","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance","volume":"125","author":"Huh","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jcv.2015.11.015","article-title":"Triage of HPV positive women in cervical cancer screening","volume":"76","author":"Wentzensen","year":"2016","journal-title":"J. Clin. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/cncy.21800","article-title":"Interobserver reproducibility of cytologic p16(INK4a)\/Ki-67 dual immunostaining in human papillomavirus-positive women","volume":"125","author":"Benevolo","year":"2017","journal-title":"Cancer Cytopathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"djv257","DOI":"10.1093\/jnci\/djv257","article-title":"p16\/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women","volume":"107","author":"Wentzensen","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamainternmed.2019.0306","article-title":"Clinical Evaluation of Human Papillomavirus Screening with p16\/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program","volume":"179","author":"Wentzensen","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jamaoncol.2018.4270","article-title":"Five-Year Risk of Cervical Precancer Following p16\/Ki-67 Dual-Stain Triage of HPV-Positive Women","volume":"5","author":"Clarke","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/jnci\/djt235","article-title":"Screening for cervical cancer precursors with p16\/Ki-67 dual-stained cytology: Results of the PALMS study","volume":"105","author":"Ikenberg","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(11)70188-7","article-title":"Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: A subanalysis of the ATHENA study","volume":"12","author":"Castle","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/jwh.2020.8849","article-title":"Cervical cancer screening in postmenopausal women: Is it time to move toward primary high-risk human papillomavirus screening?","volume":"30","author":"Kiff","year":"2021","journal-title":"J. Women Health"},{"key":"ref_28","unstructured":"Serbian Cancer Registry (2024). Malignant Tumours in Republic of Serbia 2023, Department for Prevention and Control of Non-communicable Diseases, Institute of Public Health of Serbia \u201cDr Milan Jovanovi\u0107 Batut\u201d. Available online: https:\/\/www.batut.org.rs\/download\/publikacije\/MaligniTumoriuRepubliciSrbiji2023.pdf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41416-020-0790-1","article-title":"Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening","volume":"122","author":"Hashim","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_30","first-page":"75","article-title":"Updates in Cervical Cancer Screening Guidelines, The Bethesda System for Reporting Cervical Cytology, and Clinical Management Recommendations","volume":"3","author":"Wang","year":"2023","journal-title":"J. Clin. Transl. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5114\/pjp.2024.135828","article-title":"Retrospective analysis of negative cytology results correlated with a positive high-risk in the human papillomavirus result and subsequent results of patients over a period of three years","volume":"75","author":"Piotrowski","year":"2024","journal-title":"Pol. J. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13027-023-00531-w","article-title":"Do women with high-risk HPV E6\/E7 mRNA test positivity and NILM cytology need colposcopy?","volume":"18","author":"Liu","year":"2023","journal-title":"Infect. Agents Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"S\u00f8rbye, S.W., Falang, B.M., Antonsen, M., and Richardsen, E. (2026). Cervical Cytology and HPV16\/18\/45 mRNA Co-Testing Improve Risk Stratification in Routine Clinical Practice. Cancers, 18.","DOI":"10.3390\/cancers18050834"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Gui, T., Chen, Z., and Chen, F. (2021). Validation of the indication for colposcopy proposed by the 2019 ASCCP risk-based management consensus guidelines: A single-center study in China. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0253493"},{"key":"ref_35","unstructured":"Wojciechowska, U., Bara\u0144ska, K., Micha\u0142ek, I., Olasek, P., Mikleska, M., and Didkowska, J.A. (2022). Nowotwory Z\u0142o\u015bliwe w Polsce 2020 Roku, Biuletyn Krajowego Rejestru Nowotwor\u00f3w."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00404-023-07281-5","article-title":"The use of colposcopy for triage in HPV-positive women aged 65 years and older","volume":"309","author":"Kuenkel","year":"2024","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bruno, M.T., Valenti, G., Cavallaro, A.G., Palermo, I., Aiello, T., Farina, J., Panella, M.M., and Mereu, L. (2024). Extended genotyping to stratify the risk of CIN2+ in women with persistent HPV infection, negative cytology and type 3 transformation zone. Cancers, 16.","DOI":"10.3390\/cancers16101816"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"03000605251383687","DOI":"10.1177\/03000605251383687","article-title":"Smoking exposure and cervical cancer risk: Integrating observational and genetic evidence","volume":"53","author":"Su","year":"2025","journal-title":"J. Int. Med. Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zhen, S., Hu, C.M., and Bian, L.H. (2013). Glutathione S-transferase polymorphism interactions with smoking status and HPV infection in cervical cancer risk: An evidence-based meta-analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083497"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3349\/ymj.2007.48.2.192","article-title":"Associations between smoking, screening, and death caused by cervical cancer in Korean women","volume":"48","author":"Odongua","year":"2007","journal-title":"Yonsei Med. J."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Karnik, M., Tulimilli, S.V., Anantharaju, P.G., Bettadapura, A.D.S., Natraj, S.M., Mohideen, H.S., Dovat, S., Sharma, A., and Madhunapantula, S.V. (2026). An Overview of the Mechanisms of HPV-Induced Cervical Cancer: The Role of Kinase Targets in Pathogenesis and Drug Resistance. Cancers, 18.","DOI":"10.3390\/cancers18020318"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3349\/ymj.2002.43.6.712","article-title":"GSTP1 polymorphism, cigarette smoking and cervical cancer risk in Korean women","volume":"43","author":"Jee","year":"2002","journal-title":"Yonsei Med. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1034\/j.1600-0412.1998.770617.x","article-title":"Cigarette smoking and high-risk HPV DNA as predisposing factors for high-grade cervical intraepithelial neoplasia (CIN) in young Brazilian women","volume":"77","author":"Panetta","year":"1998","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejogrb.2024.09.003","article-title":"Optimization of HPV-positive women triage with p16\/Ki67 dual staining cytology in an organized cervical cancer screening program in the center region of Portugal","volume":"302","author":"Sepodes","year":"2024","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/ijc.33812","article-title":"Clinical validation of p16\/Ki-67 dual-stained cytology triage of HPV-positive women: Results from the IMPACT trial","volume":"150","author":"Wright","year":"2022","journal-title":"Int. J. Cancer"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1493\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:20:39Z","timestamp":1785756039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medicina62081493"],"URL":"https:\/\/doi.org\/10.3390\/medicina62081493","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}